149 related articles for article (PubMed ID: 21814778)
1. Expression of JL1 in Burkitt lymphoma is associated with improved overall survival.
Hwang I; Go H; Jeon YK; Ko YH; Yoon DH; Suh C; Huh JR; Lee H; Gil M; Park CS
Virchows Arch; 2011 Oct; 459(4):353-9. PubMed ID: 21814778
[TBL] [Abstract][Full Text] [Related]
2. JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma.
Kim MS; Park CJ; Cho YU; Jang S; Seo EJ; Park CS; Huh J; Im HJ; Seo JJ; Yoon DH; Suh C
Ann Lab Med; 2020 Jan; 40(1):1-6. PubMed ID: 31432632
[TBL] [Abstract][Full Text] [Related]
3. Expression of JL1 is an effective adjunctive marker of leukemia cutis.
Park YS; Park SH; Park SJ; Kim Y; Jang KT; Ko YH; Lee MW; Huh JR; Park CS
Arch Pathol Lab Med; 2010 Jan; 134(1):95-102. PubMed ID: 20073611
[TBL] [Abstract][Full Text] [Related]
4. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
5. The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in
Park SH; You E; Park CJ; Jang S; Cho YU; Yoon CH; Koh KN; Im HJ; Seo JJ
Ann Lab Med; 2019 Jul; 39(4):358-366. PubMed ID: 30809981
[TBL] [Abstract][Full Text] [Related]
6. Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.
Gualco G; Queiroga EM; Weiss LM; Klumb CE; Harrington WJ; Bacchi CE
Hum Pathol; 2009 Apr; 40(4):565-71. PubMed ID: 19144381
[TBL] [Abstract][Full Text] [Related]
7. A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias.
Park WS; Bae YM; Chung DH; Kim TJ; Choi EY; Chung JK; Lee MC; Park SY; Park MH; Park SH
Leukemia; 1998 Oct; 12(10):1583-90. PubMed ID: 9766503
[TBL] [Abstract][Full Text] [Related]
8. Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma.
Valencia-Hipόlito A; Hernández-Atenógenes M; Vega GG; Maldonado-Valenzuela A; Ramon G; Mayani H; Peña Alonso Y; Martinez-Maza O; Méndez-Tenorio A; Huerta-Yepez S; Bonavida B; Vega MI
Leuk Lymphoma; 2014 Aug; 55(8):1806-14. PubMed ID: 24067139
[TBL] [Abstract][Full Text] [Related]
9. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
McClure RF; Remstein ED; Macon WR; Dewald GW; Habermann TM; Hoering A; Kurtin PJ
Am J Surg Pathol; 2005 Dec; 29(12):1652-60. PubMed ID: 16327438
[TBL] [Abstract][Full Text] [Related]
10. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
Nasr MR; Rosenthal N; Syrbu S
Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
[TBL] [Abstract][Full Text] [Related]
11. JL1, a novel differentiation antigen of human cortical thymocyte.
Park SH; Bae YM; Kwon HJ; Kim TJ; Kim J; Lee SJ; Lee SK
J Exp Med; 1993 Oct; 178(4):1447-51. PubMed ID: 8376947
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
Sakarou M; Eisele L; Dührsen U; Hüttmann A
Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
[TBL] [Abstract][Full Text] [Related]
13. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.
Zeng L; Huang W; Cao Z; Zheng B; Liu X; Guo L; Feng X
Ann Hematol; 2019 Jun; 98(6):1467-1476. PubMed ID: 30895352
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
[TBL] [Abstract][Full Text] [Related]
15. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.
Magrath IT; Janus C; Edwards BK; Spiegel R; Jaffe ES; Berard CW; Miliauskas J; Morris K; Barnwell R
Blood; 1984 May; 63(5):1102-11. PubMed ID: 6546890
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels.
Kim HD; Cho H; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Kim SJ; Ko YH; Kim WS; Suh C
Cancer Res Treat; 2021 Jul; 53(3):847-856. PubMed ID: 33332932
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
18. Low expression of Mda-7/IL-24 and high expression of C-myb in tumour tissues are predictors of poor prognosis for Burkitt lymphoma patients.
Ma M; Zhao R; Yang X; Zhao L; Liu L; Zhang C; Wang X; Shan B
Hematology; 2018 Sep; 23(8):448-455. PubMed ID: 29415639
[TBL] [Abstract][Full Text] [Related]
19. Use of the JL1 epitope, which encompasses the nonglycosylation site of CD43, as a marker of immature/neoplastic Langerhans cells.
Park HJ; Jeon YK; Lee AH; Oh YH; Park SH; Jung KC
Am J Surg Pathol; 2012 Aug; 36(8):1150-7. PubMed ID: 22790855
[TBL] [Abstract][Full Text] [Related]
20. Sporadic and endemic Burkitt lymphoma have frequent
Zhou P; Blain AE; Newman AM; Zaka M; Chagaluka G; Adlar FR; Offor UT; Broadbent C; Chaytor L; Whitehead A; Hall A; O'Connor H; Van Noorden S; Lampert I; Bailey S; Molyneux E; Bacon CM; Bomken S; Rand V
Blood Adv; 2019 Jul; 3(14):2118-2127. PubMed ID: 31300419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
